Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Trial to Evaluate the Safety and Efficacy of Afamelanotide as a DNA Regenerative Therapy in Xeroderma Pigmentosum C and V patients

X
Trial Profile

A Clinical Trial to Evaluate the Safety and Efficacy of Afamelanotide as a DNA Regenerative Therapy in Xeroderma Pigmentosum C and V patients

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afamelanotide (Primary)
  • Indications Xeroderma pigmentosum
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CUV153
  • Sponsors Clinuvel Pharmaceuticals
  • Most Recent Events

    • 23 Jun 2022 According to a Clinuvel media release, the company plans to discuss filing a dossier from CUV156, CUV151, CUV152, CUV153, and CUV154 with regulatory authorities, in order to seek marketing authorisation for afamelanotide for XP.
    • 10 May 2021 New trial record
    • 23 Mar 2021 According to a Clinuvel Pharmaceuticals media release, the company has expanded its clinical program to evaluate includes patients with the rare disorders XP-V and XP-C. Having reached agreement with clinical and academic experts, the company will generate clinical data on the safety and efficacy of SCENESSE (afamelanotide 16mg).In this trial, SCENESSE (afamelanotide 16mg) to be evaluated in xeroderma pigmentosum variant (XP-V).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top